Open AccessPlacebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Author(s) -
Gıancarlo Comı,
Douglas Jeffery,
Ludwig Kappos,
Xavier Montalbán,
Alexey Boyко,
Maria A. Rocca,
Massimo Filippi
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1104318
Subject(s) - medicine , placebo , multiple sclerosis , hazard ratio , expanded disability status scale , confidence interval , randomized controlled trial , clinical endpoint , magnetic resonance imaging , gastroenterology , surgery , pathology , radiology , immunology , alternative medicine
Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing-remitting multiple sclerosis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom